Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?
Fluoro-deoxyglucose (FDG) is a metabolic marker, which follows the same route into cells as that of glucose, and it can be radiolabelled with fluorine-18, 18F-FDG making it suitable for imaging with positron emission tomography (PET). The fact that rapidly proliferating cells such as tumour cells accumulate 18F-FDG more avidly than those with a normal turnover rate has given rise to its potential in oncology. The rationale and previous published uses of 18F-FDG in oncology are reviewed, together with the various analysis techniques and associated methodological difficulties.
Brock
C S
CS
M.R.C. Cyclotron Unit, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK.
Meikle
S R
SR
Price
P
P
D003847:Deoxyglucose / Q000031:analogs & derivatives*; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D009369:Neoplasms / Q000000981:diagnostic imaging*; D014055:Tomography, Emission-Computed / Q000706:statistics & numerical data
D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose